變更

4. Yujun Li, Qi Yang, Liquan Yang, Ning Lei and Ke Zheng* “A scalable electrochemical dehydrogenative cross-coupling of P(O)H compounds with RSH/ROH” Chem. Commun., 2019, 55, 4981-4984.

5. Angelo Aguilar, # Ke Zheng, # et al. and Shaomeng Wang * “Structure-Based Discovery of M-89 as a Highly Potent Inhibitor of the Menin-Mixed Lineage Leukemia (Menin-MLL) Protein-Protein Interaction” J. Med. Chem. 2019, 62, 6015−6034.

8. Shilin Xu#, Angelo Aguilar#, Tianfeng Xu#, Ke Zheng#, et al. and Shaomeng Wang * “Design of the First-in-Class, Highly Potent Irreversible Inhibitor Targeting the Menin-MLL Protein–Protein Interaction” Angew. Chem. Int. Ed. 2018, 57, 1601−1605.

9. Ke Zheng, Chul Min Park, Sarah Iqbal, Pamela Hernandez, HaJeung Park, Philip V. LoGrasso,* and Yangbo Feng* “Pyridopyrimidinone Derivatives as Potent and Selective c-Jun N-Terminal Kinase (JNK) Inhibitors” ACS Med. Chem. Lett., 2015, 6, 413-418.

10. Yan Yin, Ke Zheng, Nibal Eid, et al, Philip V. LoGrasso,* and Yangbo Feng*“Bis-aryl Urea Derivatives as Potent and Selective LIM Kinase (Limk) Inhibitors” J. Med. Chem. 2015, 58(4), 1846-1861.

11. Ke Zheng, Sarah Iqbal, Pamela Hernandez, HaJeung Park, Philip V. LoGrasso,* and Yangbo Feng* “Design and Synthesis of Highly Potent and Selective JNK3 Inhibitors: SAR Studies on Aminopyrozal Derivatives” J. Med. Chem. 2014, 57, 10013-10030